Cite
HARVARD Citation
Vergote, I. et al. (2019). Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet oncology. 20 (6), pp. 862-876. [Online].